https://www.thebodypro.com/category/managing-hiv-drug-resistance-pro
HIV Treatment Strategies

Managing HIV Drug Resistance

The Latest

Close-up of a blue-eyed senior man
News

This Week in HIV Research: Older and Wiser

July 8, 2021: Trends among heavily treatment-experienced PLWH; a new look at peripheral neuropathy factors; heart transplantation in PLWH; complications following successful HCV treatment.

By Barbara Jungwirth and Myles Helfand
Truvada
News

This Week in HIV Research: The Realities of PrEP

June 17, 2021: PrEP awareness vs. PrEP willingness among young Black women; acute HIV infection during PrEP initiation; real-world PrEP efficacy; HIV rates by U.S. region among transgender people.

By Barbara Jungwirth and Myles Helfand
doctor desk
Features

Long-Acting ART Rollout: 3 Considerations for Clinicians

Four months after the approval of cabotegravir/rilpivirine, medical providers still face some tough questions about who might best benefit and how the medication might be covered.

By Larry Buhl
rear view mirror
News

This Week in HIV Research: Taking Stock of Our Epidemic

Dec. 17, 2020: HIV-related mortality in the U.S.; trends in extensive multidrug resistance; 96-week fostemsavir data; statins for microbial cancer prevention.

By Barbara Jungwirth and Myles Helfand
scientists analyzing
Features

Fostemsavir, at Last: A New Treatment Option for Extensive HIV Drug Resistance

Most people living with HIV will never need fostemsavir. But for those who do, the drug can be a life-saver—and that is pretty epic.

By David Alain Wohl, M.D.
human touch
News

This Week in HIV Research: The Human Touch

Nov. 5, 2020: Success of direct referrals at re-linking people to HIV care; stable housing = viral suppression; modern-day rates of virologic failure; how pharmacy type affects HIV treatment outcomes.

By Barbara Jungwirth and Myles Helfand
maze
News

This Week in HIV Research: A Metabolic Maze

Oct. 29, 2020: Diabetes incidence on INSTIs vs. NNRTIs vs. protease inhibitors; can NRTIs fight diabetes?; from TDF to TAF in HIV/HBV-coinfected people; assessing neurocognitive impacts of older two-drug regimens.

By Barbara Jungwirth and Myles Helfand
COVID-19 mask profile
News

This Week in HIV Research: The Real-World Effects of COVID-19

Oct. 22, 2020: Impact of COVID-19 shutdowns on HIV viral suppression; unsuppressed HIV viral load despite no treatment failure; point-of-care rapid testing vs. lab testing; it's not about "what," it's about "when."

By Barbara Jungwirth and Myles Helfand
injectable
Interviews

What Are the New HIV Treatment and Prevention Drugs Under Development in 2020?

Richard Jefferys of Treatment Action Group discusses the pipeline for new modalities being explored for treatment, PrEP, vaccine, and cure.

By Terri Wilder, M.S.W.
doctor walking away
News

This Week in HIV Research: How to Fix Our Dwindling HIV Workforce

April 23, 2020: The corps of front-line care providers with HIV-specific experience is aging and retiring, leaving behind a growing need for quality care. We examine recent research and analysis that both describes that need and offers interventions to meet it.

By Barbara Jungwirth and Myles Helfand